Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

Open access
Schnitzbauer, Andreas A, Zuelke, Carl, Graeb, Christian, Rochon, Justine, Bilbao, Itxarone, Burra, Patrizia, de Jong, Koert P, Duvoux, Christophe, Kneteman, Norman M, Adam, Rene, Bechstein, Wolf O, Becker, Thomas, Beckebaum, Susanne, Chazouillères, Olivier, Cillo, Umberto, Colledan, Michele, Fändrich, Fred, Gugenheim, Jean, Hauss, Johann P, Heise, Michael, Hidalgo, Ernest, Jamieson, Neville, Königsrainer, Alfred, Lamby, Philipp E, Lerut, Jan P, Mäkisalo, Heikki, Margreiter, Raimund, Mazzaferro, Vincenzo, Mutzbauer, Ingrid, Otto, Gerd, Pageaux, Georges-Philippe, Pinna, Antonio D, Pirenne, Jacques, Rizell, Magnus, Rossi, Giorgio, Rostaing, Lionel, Roy, Andre, Turrion, Victor Sanchez, Schmidt, Jan, Troisi, Roberto I, van Hoek, Bart, Valente, Umberto, Wolf, Philippe, Wolters, Heiner, Mirza, Darius F, Scholz, Tim, Steininger, Rudolf, Soderdahl, Gunnar, Strasser, Simone I, Jauch, Karl-Walter, Neuhaus, Peter, Schlitt, Hans J, Geissler, Edward K · 2010 · BMC Cancer

Abstract

Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. Methods/Design: The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 2 1/2 -year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating. Discussion: If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC. Trial Register: Trial registered at http://www.clinicaltrials.gov: NCT00355862 (EudraCT Number: 2005-005362-36)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2407-10-190

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 161

Metadata

Authors
Schnitzbauer, A. A., Zuelke, C., Graeb, C., Rochon, J., Bilbao, I., Burra, P., de Jong, K. P., Duvoux, C., Kneteman, N. M., Adam, R., Bechstein, W. O., Becker, T., Beckebaum, S., Chazouillères, O., Cillo, U., Colledan, M., Fändrich, F., Gugenheim, J., Hauss, J. P., Heise, M., Hidalgo, E., Jamieson, N., Königsrainer, A., Lamby, P. E., Lerut, J. P., Mäkisalo, H., Margreiter, R., Mazzaferro, V., Mutzbauer, I., Otto, G., Pageaux, G.-P., Pinna, A. D., Pirenne, J., Rizell, M., Rossi, G., Rostaing, L., Roy, A., Turrion, V. S., Schmidt, J., Troisi, R. I., van Hoek, B., Valente, U., Wolf, P., Wolters, H., Mirza, D. F., Scholz, T., Steininger, R., Soderdahl, G., Strasser, S. I., Jauch, K.-W., Neuhaus, P., Schlitt, H. J., & Geissler, E. K.
Venue
BMC Cancer
Published
2010-05-11
Volume
10
Issue
1
Pages
190-190
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2143386010
Cited by
161
References
1
FWCI
12.98
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1186/1471-2407-10-190
The paper
Schnitzbauer, A. A., Zuelke, C., Graeb, C., Rochon, J., Bilbao, I., Burra, P., de Jong, K. P., Duvoux, C., Kneteman, N. M., Adam, R., Bechstein, W. O., Becker, T., Beckebaum, S., Chazouillères, O., Cillo, U., Colledan, M., Fändrich, F., Gugenheim, J., Hauss, J. P., . . . Geissler, E. K. (2010). A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. https://doi.org/10.1186/1471-2407-10-190

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.